Steffan Joe's Album: Wall Photos
In vitro ADME
testing services market is likely to be worth USD 2.2 billion by 2030,
predicts Roots Analysis
With increasing cases of drug failure, due to
problems associated with pharmacokinetic profiles of candidate therapies, absorption,
distribution, metabolism and excretion (ADME) properties and inherent toxicity, industry players are
actively looking for more advanced solutions.
Roots Analysis has announced the
addition of “In
Vitro ADME Testing Services Market, 2019-2030” report to its list of offerings.
According to the US
Food and Drug Administration (USFDA), less than 10% of investigational new drug
(IND) candidates progress beyond the submission of a new drug application
(NDA); this implies that majority of the drug / therapy candidates fail to
reach the market owing to unacceptable safety and efficacy profiles and the
problems associated with their pharmacokinetic profiles, ADME properties and
inherent toxicity. ADME studies are considered to be critical in establishing
the safety and efficacy of drug candidates.
To order this 280+ page report, which features 135+ figures
and 120+ tables, please visit this
- https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html
Key Market Insights
Nearly 100 players
currently claim to provide in vitro ADME testing services
Nearly 60% of these
companies are small and mid-sized firms. Further, close to 35% of the CROs
engaged in this domain, claim to provide services to both pharmaceutical
companies and academic institutes.
Nearly 80% of in
vitro ADME testing service
providers are based in the developed geographies
Within North America,
the US has the maximum number of players, whereas, in Europe, most of the
service providers are distributed across France, Germany, the UK, and Spain. On
the other hand, there are companies that are using this approach for drug
discovery operations, in emerging regions, such as Australia, India and China,
as well.
Over 85% companies claim to offer assays for drug
metabolism and elimination testing
Further, nearly 70%
companies claim to have capabilities to conduct absorption and distribution
related studies, respectively. It is worth mentioning that about 35% of players
presently offer end-to-end drug discovery services.
Nearly 95% CROs have
received operational approval and certification from the USFDA
In addition,
companies have received necessary certifications from the EMA (50%), MHLW /
PMDA (15%), ICH (13%), WHO (11%), MHRA (11%), followed by CFDA / MFDS / SFDA
(9%) and TGA (4%).
Over 35 acquisitions have taken place amongst various
stakeholders, between 2005-2018
The addition of
capabilities (primarily related to drug metabolism and pharmacokinetics
testing) emerged as the most important value drivers across all the
acquisitions. Other key value drivers include geographical consolidation and
geographical expansion.
North America and
Europe are anticipated to capture over 70% of the market share by 2030
Within
North America, US is anticipated to hold the 90% of the market share. It is
worth mentioning that the market in Asia-Pacific region is anticipated to grow
at a relatively faster rate (~11%).
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/239/request-sample.html
Key
Questions Answered
§ Who
are the leading CROs offering in vitro ADME testing services?
§ What
are the key services being offered by in vitro ADME testing service
providers?
§ What
is the trend of mergers and acquisitions in this domain?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§
What are the anticipated future trends related to in
vitro ADME testing services market?
The report also
features inputs from a number of eminent industry stakeholders. In fact, one of
the experts interviewed concurred on the opinion that the drug developers
today, prefer to opt for contract service providers that offer a range of capabilities,
such as design, synthesis, initial scale-up, in vitro ADME testing, safety pharmacology, under one roof; this
guarantees a certain degree of ease of operation, and enables sponsors to
shortlist and rely on a capable partner for their outsourcing requirements.” The report features detailed
transcripts of discussions held with the following individuals:
The research covers
detailed profiles and assesses product portfolios of several companies,
including (illustrative list, no
selection criteria):
§ Albany
Molecular Research (AMRI)
§ Charles
River Laboratories
§ Pharmaceutical
Product Development (PPD)
§ RTI
International
§ Eurofins
Scientific
§ Evotec
§ Galapagos
§ Tecan
Group
§ GVK
Biosciences
§ Pharmaron
§ Sai
Life Sciences
§ Shanghai
Medicilon
§ WuXi
AppTec
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html or email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
In Silico / Computer-Aided Drug Discovery
Services Market: Focus on Large Molecules, 2020-2030
2.
AR / VR based Healthcare Digital
Marketing Service Providers Market, 2020-2030
3.
Bioavailability Enhancement
Technologies and Services Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
testing services market is likely to be worth USD 2.2 billion by 2030,
predicts Roots Analysis
With increasing cases of drug failure, due to
problems associated with pharmacokinetic profiles of candidate therapies, absorption,
distribution, metabolism and excretion (ADME) properties and inherent toxicity, industry players are
actively looking for more advanced solutions.
Roots Analysis has announced the
addition of “In
Vitro ADME Testing Services Market, 2019-2030” report to its list of offerings.
According to the US
Food and Drug Administration (USFDA), less than 10% of investigational new drug
(IND) candidates progress beyond the submission of a new drug application
(NDA); this implies that majority of the drug / therapy candidates fail to
reach the market owing to unacceptable safety and efficacy profiles and the
problems associated with their pharmacokinetic profiles, ADME properties and
inherent toxicity. ADME studies are considered to be critical in establishing
the safety and efficacy of drug candidates.
To order this 280+ page report, which features 135+ figures
and 120+ tables, please visit this
- https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html
Key Market Insights
Nearly 100 players
currently claim to provide in vitro ADME testing services
Nearly 60% of these
companies are small and mid-sized firms. Further, close to 35% of the CROs
engaged in this domain, claim to provide services to both pharmaceutical
companies and academic institutes.
Nearly 80% of in
vitro ADME testing service
providers are based in the developed geographies
Within North America,
the US has the maximum number of players, whereas, in Europe, most of the
service providers are distributed across France, Germany, the UK, and Spain. On
the other hand, there are companies that are using this approach for drug
discovery operations, in emerging regions, such as Australia, India and China,
as well.
Over 85% companies claim to offer assays for drug
metabolism and elimination testing
Further, nearly 70%
companies claim to have capabilities to conduct absorption and distribution
related studies, respectively. It is worth mentioning that about 35% of players
presently offer end-to-end drug discovery services.
Nearly 95% CROs have
received operational approval and certification from the USFDA
In addition,
companies have received necessary certifications from the EMA (50%), MHLW /
PMDA (15%), ICH (13%), WHO (11%), MHRA (11%), followed by CFDA / MFDS / SFDA
(9%) and TGA (4%).
Over 35 acquisitions have taken place amongst various
stakeholders, between 2005-2018
The addition of
capabilities (primarily related to drug metabolism and pharmacokinetics
testing) emerged as the most important value drivers across all the
acquisitions. Other key value drivers include geographical consolidation and
geographical expansion.
North America and
Europe are anticipated to capture over 70% of the market share by 2030
Within
North America, US is anticipated to hold the 90% of the market share. It is
worth mentioning that the market in Asia-Pacific region is anticipated to grow
at a relatively faster rate (~11%).
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/239/request-sample.html
Key
Questions Answered
§ Who
are the leading CROs offering in vitro ADME testing services?
§ What
are the key services being offered by in vitro ADME testing service
providers?
§ What
is the trend of mergers and acquisitions in this domain?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§
What are the anticipated future trends related to in
vitro ADME testing services market?
The report also
features inputs from a number of eminent industry stakeholders. In fact, one of
the experts interviewed concurred on the opinion that the drug developers
today, prefer to opt for contract service providers that offer a range of capabilities,
such as design, synthesis, initial scale-up, in vitro ADME testing, safety pharmacology, under one roof; this
guarantees a certain degree of ease of operation, and enables sponsors to
shortlist and rely on a capable partner for their outsourcing requirements.” The report features detailed
transcripts of discussions held with the following individuals:
The research covers
detailed profiles and assesses product portfolios of several companies,
including (illustrative list, no
selection criteria):
§ Albany
Molecular Research (AMRI)
§ Charles
River Laboratories
§ Pharmaceutical
Product Development (PPD)
§ RTI
International
§ Eurofins
Scientific
§ Evotec
§ Galapagos
§ Tecan
Group
§ GVK
Biosciences
§ Pharmaron
§ Sai
Life Sciences
§ Shanghai
Medicilon
§ WuXi
AppTec
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/in-vitro-adme-testing-services-market-2019-2030/239.html or email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
In Silico / Computer-Aided Drug Discovery
Services Market: Focus on Large Molecules, 2020-2030
2.
AR / VR based Healthcare Digital
Marketing Service Providers Market, 2020-2030
3.
Bioavailability Enhancement
Technologies and Services Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
ben.johnson@rootsanalysis.com
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis